A 2026 preclinical study found behavioral and hippocampal changes in animal models, raising interest in cognitive effects
Preclinical studies in animal models have demonstrated that survodutide effectively activates both GLP-1R and GCGR, resulting in reduced body weight, slower gastric emptying, decreased energy intake, increased energy expenditure, and improved glucose tolerance [86]
An individuals lifestyle, diet, genetics, and how well they respond to the medication also play a role
Numerous clinical trials have validated the effectiveness of Tirzepatide in reducing cumulative caloric intake, especially when paired with lifestyle modifications
Protein matters most here because it supports muscle maintenance while helping the snack feel satisfying